IMA: Olevaprubart advances in phase IIb with robust efficacy, safety, and funding into 2028
Olevaprubart, a next-generation OX40-targeting antibody, is in phase IIb trials for atopic dermatitis and alopecia areata, with strong early efficacy and a favorable safety profile. Top-line data is expected in Q4 next year, and the company is well-funded into 2028.Based on ImageneBio, Inc. [IMA] H…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.